GLP1R and Insulin resistance: Weight management is a key intervention for mitigating insulin resistance and T2D, and the widely used glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an elevated risk of sarcopenia [14,15,16,17].